Training in the Design and Development of Infectious Disease Therapeutics

传染病治疗药物设计和开发培训

• 批准号: 10447715
• 负责人: Richard E. Lee
• 金额: $ 22.32万
• 依托单位: ST. JUDE CHILDREN'S RESEARCH HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-07-08 至 2026-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10447715
• 关键词: Communicable Diseases; Development; Therapeutic; Training; design

Project Summary/Abstract Infectious diseases remain the leading cause of death of children worldwide. New therapeutics are urgently needed to replace current treatments that are being compromised by drug resistance and emerging threats. The current COVID-19 pandemic perfectly illustrates the urgency. St. Jude Children’s Research Hospital (SJCRH) is the ideal pediatric research and treatment center to train postdoctoral fellows in this effort. The hospital’s translational and collaborative research environment combined with its expertise and infrastructure have a proven track record of successful therapeutic development. Our pediatric patients, particularly those treated for cancer, are typically immunocompromised and are at risk from a wide variety of infectious agents and pathogens that evolve more rapidly without immune clearance. SJCRH has developed an internationally recognized infectious disease program that dates from its establishment over 50 years ago. This program includes major research efforts in therapeutic and prophylactic strategies for bacterial, viral and fungal infectious agents. The training program leverages these strengths and the strong history of developing new therapeutics to provide unique and enhanced research training to postdoctoral fellows. The 16 preceptors in the program are from the departments of Infectious Diseases, Structural Biology, Chemical Biology & Therapeutics, Immunology and Pharmaceutical Sciences. They bring complementary expertise to this enterprise that not only seeks to understand the biology of infection but also strives to develop therapies to combat them. This expertise includes drug discovery, high-throughput screening, medicinal chemistry, immune responses to infection and therapies, and vaccine platforms and adjuvants. These efforts are linked to on-site best in class capabilities in GMP manufacturing and clinical trials. The broad goals of the program are to characterize pathogenic mechanisms, identify targets for therapeutic intervention, and develop vaccines and lead drug compounds that progress through the state-of-the-art therapeutics development infrastructure into safe and effective medicines. Collaborations between the preceptors provide a cross-disciplinary approach to the training program. In addition, 4 clinical collaborators will provide training in patient care, clinical trials and international medicine, and 5 training collaborators will provide training in specialized techniques. All trainees will be instructed in grant writing, rigor and reproducibility, ethics and mentoring. Interactions with pharmaceutical companies and visits to international sites in conjunction with the SJCRH Global Program are integral parts of the curriculum. To promote independence, trainees will develop their own research projects guided by a ‘team’ of mentors and apply for independent funding. We request support for three postdoctoral trainees, and the program will continue its efforts to recruit URM trainees by providing institutional support for an additional URM trainee. Finally, a formal evaluation process led by an External Advisory Committee has been established to track success and identify areas for improvement.

项目概要/摘要 传染病仍然是全世界儿童死亡的主要原因。新疗法刻不容缓 需要取代目前因耐药性和新出现的威胁而受到损害的治疗方法。 当前的 COVID-19 大流行充分说明了紧迫性。圣裘德儿童研究医院 （SJCRH）是培训博士后研究员的理想儿科研究和治疗中心。这 医院的转化和协作研究环境与其专业知识和基础设施相结合 拥有成功治疗开发的良好记录。我们的儿科患者，特别是那些 接受癌症治疗，通常免疫功能低下，并且面临多种传染源的风险 以及在没有免疫清除的情况下进化得更快的病原体。 SJCRH开发了国际 公认的传染病计划，其成立已有 50 多年的历史。这个节目 包括细菌、病毒和真菌的治疗和预防策略方面的主要研究工作 传染源。该培训计划利用了这些优势以及开发新产品的悠久历史 疗法为博士后研究员提供独特和强化的研究培训。 16位导师 该项目来自传染病、结构生物学、化学生物学和 治疗学、免疫学和制药科学。他们为此带来了互补的专业知识 该企业不仅致力于了解感染的生物学，还致力于开发治​​疗方法 与他们战斗。这些专业知识包括药物发现、高通量筛选、药物化学、 对感染和治疗的免疫反应，以及疫苗平台和佐剂。这些努力与 在 GMP 制造和临床试验方面拥有一流的现场能力。该计划的总体目标 的目的是确定致病机制的特征，确定治疗干预的目标，并开发 通过最先进的疗法取得进展的疫苗和先导药物化合物 将基础设施开发成安全有效的药物。导师之间的合作 为培训计划提供跨学科的方法。此外，4名临床合作者将提供 患者护理、临床试验和国际医学方面的培训，5 名培训合作者将提供 专业技术培训。所有学员都将接受有关资助写作、严谨性和可重复性、道德规范的指导 和指导。与制药公司互动并联合参观国际工厂 SJCRH 全球计划是课程的组成部分。为了促进独立性，学员将 在导师“团队”的指导下开发自己的研究项目并申请独立资助。我们 请求支持三名博士后实习生，项目将继续努力招募URM实习生 为额外的 URM 实习生提供机构支持。最后，由专家领导的正式评估过程 已成立外部咨询委员会来跟踪成功情况并确定需要改进的领域。